ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Late-Breaking 2016"

  • Abstract Number: 9L • 2016 ACR/ARHP Annual Meeting

    Efficacy and Safety of Canakinumab in Patients with Colchicine-Resistant Familial Mediterranean Fever, Hyper-Immunoglobulin D Syndrome/Mevalonate Kinase Deficiency and TNF Receptor-Associated Periodic Syndrome: 40 Week Results from the Pivotal Phase 3 Umbrella Cluster Trial

    Fabrizio De Benedetti1, Joost Frenkel2, Inmaculada Calvo3, Marco Gattorno4, Michel Moutschen5, Pierre Quartier6, Ozgur Kasapcopur7, Seza Ozen8, Jordi Anton9, Isabelle Koné-Paut10, Helen Lachmann11, Hal M. Hoffman12, Eldad Ben-Chetrit13, Anna Shcherbina14, Michaël Hofer15, Philip J Hashkes16, Andrew Zeft17, Karine Lheritier18, Yankun Gong19, Antonio Speziale18 and Guido Junge18, 1Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Rome, Italy, 2University Medical Center Utrecht, Utrecht, Netherlands, 3Pediatric Rheumatology, Hospital Universitario i Politecnic La Fe, Valencia, Spain, 4Pediatric Rheumatology, G. Gaslini Institute, Genoa, Italy, 5C.H.U. Sart-Tilman, Liege, Belgium, 6Necker-Enfants Malades Hospital, Paris, France, 7Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey, 8Department of Pediatrics, Division of Rheumatology, Hacettepe University Children's Hospital, Ankara, Turkey, 9Hospital Sant Joan de Déu, Barcelona, Spain, 10Department of Paediatric Rheumatology, Hôpital Kremlin Bicetre, University of Paris SUD, Paris, France, 11UK National Amyloidosis Centre, University College London Medical School, London, United Kingdom, 12University of California, San Diego, La Jolla, CA, 13Rheumatology Unit, Hadassah—Hebrew University Medical Center, Jerusalem, Israel, 14Immunology, Federal Research and Clinical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation, 15Unité romande d’immuno-rhumatologie pédiatrique, CHUV, University of Lausanne, Lausanne, Switzerland, 16Pediatrics Rheumatology; Shaare-Zedek Medical Center, Jerusalem, Israel, 17Pediatrics Rheumatology, Cleveland Clinic, Cleveland, OH, 18Novartis Pharma AG, Basel, Switzerland, 19Beijing Novartis Pharma Co. Ltd., Beijing, China

    Background/Purpose:  Evidence points to the role of abnormal IL-1β production in familial Mediterranean fever (FMF), hyper-immunoglobulin D syndrome/mevalonate kinase deficiency (HIDS/MKD) and TNF receptor-associated periodic…
  • Abstract Number: 10L • 2016 ACR/ARHP Annual Meeting

    Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors: OPAL Beyond, a Randomized, Double Blind, Placebo-Controlled, Phase 3 Trial

    Dafna D Gladman1, William Rigby2, Valderilio F Azevedo3, Frank Behrens4, Ricardo Blanco5, Andrzej Kaszuba6, Elizabeth Kudlacz7, Cunshan Wang7, Sujatha Menon7, Thijs Hendrikx8 and Keith S Kanik7, 1University of Toronto, Toronto, ON, Canada, 2Rheumatology, Dartmouth-Hitchcock Med Ctr, Lebanon, NH, 3Federal University of Parana and Edumed Health Research Center and Biotech, Curitiba, Brazil, 4Johann Wolfgang Goethe University, Frankfurt, Germany, 5Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, 6Specialstyczne Gabinety Lerkarskie "DERMED", Lodz, Poland, 7Pfizer Inc, Groton, CT, 8Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for treatment of PsA. In this first study of tofacitinib in patients (pts) with active…
  • Abstract Number: 11L • 2016 ACR/ARHP Annual Meeting

    BMS-986165 Is a Highly Potent and Selective Allosteric Inhibitor of Tyk2, Blocks IL-12, IL-23 and Type I Interferon Signaling and Provides for Robust Efficacy in Preclinical Models of Systemic Lupus Erythematosus and Inflammatory Bowel Disease

    Kathleen Gillooly1, Yifan Zhang1, Xiaoxia Yang1, Adriana Zupa-Fernandez1, Lihong Cheng1, Joann Strnad1, Mark Cunningham2, Elizabeth Heimrich1, Xiadi Zhou1, Jing Chen3, Charu Chaudhry3, Sha Li3, Kim McIntyre1, Julie Carman4, Ryan Moslin5, Stephen Wrobleski5, David Weinstein5 and James Burke1, 1Immunosciences Discovery Biology, Bristol-Myers Squibb, Princeton, NJ, 2Bristol-Myers Squibb, Princeton, NJ, 3Leads Discovery & Optimization, Bristol-Myers Squibb, Princeton, NJ, 4Discovery Translational Sciences Group, Bristol-Myers Squibb, Princeton, NJ, 5Immunosciences Discovery Chemistry, Bristol-Myers Squibb, Princeton, NJ

    Background/Purpose: Tyk2 mediates signaling downstream of the receptors for IL-12, IL-23 and Type I interferons, all key drivers of autoimmune disorders such as SLE. BMS-986165,…
  • Abstract Number: 12L • 2016 ACR/ARHP Annual Meeting

    Efficacy and Safety of Atacicept in Patients with Systemic Lupus Erythematosus: Results of a 24-Week Randomized, Placebo-Controlled, Phase IIb Study

    Joan T. Merrill1, Daniel J. Wallace2, Stephen Wax3, Amy Kao4, Patricia Fraser4, Wai Chin4 and David A. Isenberg5, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of California Los Angeles, Los Angeles, CA, 3EMD Serono, BIllerica, MA, 4EMD Serono, Billerica, MA, 5University College Hospital, London, London, United Kingdom

    Background/Purpose: Atacicept targets B-cell stimulating factors BLyS and APRIL. In the APRIL-SLE trial, atacicept 150 mg was associated with reduced SLE flares in post-hoc analyses.1Methods:…
  • « Previous Page
  • 1
  • 2
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology